Trials / Completed
CompletedNCT00004578
ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects
Phase I/II Study of ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naive HIV-Infected Patients
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the safety, tolerability and antiviral activity of lopinavir/ritonavir when administered orally in antiretroviral-HIV-1 infected subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lopinavir/Ritonavir | Lopinavir, range from 200 mg to 400 mg, every 12 hrs and Ritonavir, range from 100 mg to 200 mg, every 12 hrs |
| DRUG | Lamivudine | 150 mg, every 12 hours |
| DRUG | Stavudine | 40 mg every 12 hours |
Timeline
- Start date
- 1997-11-01
- Primary completion
- 2005-04-01
- Completion
- 2005-04-01
- First posted
- 2001-08-31
- Last updated
- 2008-04-03
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00004578. Inclusion in this directory is not an endorsement.